C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/519 (2006.01) A61K 31/5377 (2006.01) A61P 7/02 (2006.01) A61P 9/10 (2006.01) A61P 11/00 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2712022
The present invention relates to enantiomerically pure (-) 2-[1-(7-methyl-2- (morpholin-4-yl)-4-oxo-4H-pyrido[1,2- a]pyrimidin-9- yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase 8 and use of the selective inhibitor in e.g. anti-thrombotic therapy.
La présente invention concerne concerne l'acide (-)2-[l-(7-méthyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[l,2-a]pyrimidin-9-yl)éthylamino]benzoïque énantiomériquement pur ou ses sels pharmaceutiquement acceptables, dans un état solide, son utilisation en thérapie médicale, une composition pharmaceutique le contenant, son utilisation pour la préparation d'un médicament destiné à être utilisé dans une méthode de prévention ou de traitement de maladies, et son utilisation dans une méthode de prévention ou de traitement d'une maladie. La présente invention concerne un inhibiteur sélectif de la phosphoinositide (PI) 3-kinase ß et son utilisation, notamment dans un traitement anti-thrombotique.
Fjellstroem Ola
Gustafsson David
Jackson Shaun
Lindberg Jan A.
Astrazeneca Ab
Fetherstonhaugh & Co.
LandOfFree
Enantiomerically pure (-)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enantiomerically pure (-)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enantiomerically pure (-)... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1842397